# Growth Hormone excess and pseudoprecocious puberty in a 8 year old boy with McCune-Albright Syndrome

## Ertl Diana-Alexandra<sup>1</sup>, Gojo Johannes<sup>2</sup>, Aubrunner Daniela<sup>2</sup>, Haeusler Gabriele<sup>1</sup>


<sup>1</sup>Univ. Clinic of Paediatrics and Adolescent Medicine, Pediatric Endocrinology, Vienna, Austria <sup>2</sup>Univ. Clinic of Paediatrics and Adolescent Medicine, Pediatric Neurooncology, Vienna, Austria



## Introduction

McCune-Albright Syndrome is a pathological entity defined by skin, bone and endocrine disorders, due to activating mutations in the GNAS-1 gene. Reported cases exhibit heterogeneous clinical symptoms. The genetic analysis is an adjuvant investigation, reserved for the mild, subclinical cases. Some of the patients with clear clinical McCune- Albright features have negative results regarding GNAS mutations, as the positive detection rate has been reported to range between 23%-100% in different studies.





## Case report

The 8 year old boy, previously diagnosed with monoostotic fibrous dysplasia of the skull involving the frontal and temporal region and left optic canal, was referred due to signs of pubertal development since the age of 6 years. There was facial asymmetry due to abnormal skull bone formation (**Fig. 1 and 2**),with only one café-au-lait spot in the right subscapular area (**Fig.1**). <u>Genetic analysis</u> of *GNAS* in peripheral lymphocytes was normal, suggesting somatic mosaicism.

After clinical and biochemical assessment we had evidence that at least three hormonal axis were affected: **GH/IGF-I**:

-growth above 97<sup>th</sup> percentile and accelerated bone age.

Fig. 1: Facial asymmetry due to bone lesions (*left*) and fainted cafe-au-lait spot (*right*)




Fig. 3:Testicular ultrasound. A. longitudinal section of the left testicle: macroorhidism (10ml) and inhomogeneous structure. B. Transversal *(left)* and longitudinal *(right)* section of the right testicle: pubertal size (6ml) and normal structure

Fig. 2: Cranial MRT showing multiple bone lesions, including orbital, maxilar and mandibular involvement

## Discussion

There are few reports in the literature regarding therapy with Pegvisomant in the paediatric population with GH excess [1]. The main therapy target in this patient is lowering IGF-I, as high levels represent a risk for compression of the optic nerve by the fibrotic bone tissue [2]. Boys with MAS and signs of secondary sex characteristics are also rarely found in published reports, although testicular enlargement is common. The inconsistent result of LHRH testing with a rather low testosterone level in this case speaks for an intermittent testicular activation, like is has been described in girls with MAS and pseudoprecocious puberty. An alternative explanation is a direct stimulatory effect of IGF-I at the testicular level [3].

## -GH basal 11,4 ng/ml, IGF-I levels +4 SDS, GH excess after oral glucose load (minimal suppression of 7,7ng/dl) <u>Androgen:</u>

-pubic hair stage Tanner IV with asymmetric testicular development; testicular volume (6 and 10ml) (**Fig.3**) -elevated testosterone levels for age, but low for testicular size

-basal gonadotropins measurable, with minimal stimulation after LHRH (maximal LH 2,1 mU/ml and FSH 0,8mU/ml)

### **Prolactin:**

Hyperprolactinemia (224,8 ng/ml, n.r. 4-15,2ng/ml)

## Therapy

-Pegvisomant (Somavert ®): 10 mg daily s.c.
-Cabergoline (Dostinex ®): 2x 0,5 mg per week
During therapy growth decelerated and GH and prolactin levels normalised (Fig. 4)

An anti-androgenic therapy has so far not been started due to low testosterone levels, good height prognosis and the peripubertal age of the patient (**Fig. 5**)





Fig. 4: Bioche mical and auxological follow-up under therapy



### Fig. 5: Serum testosterone follow-up

#### Acknowledgements

We thank Michael Collins (*National Institutes Of Health, USA*) and Katharina M. Main (*University Department of Growth and Reproduction, Rigshospitalet, Copenhagen , Denmark*) for sharing their experiences with treatment of hormone excess in MAS

### References

 Main KM, Sehested A, Feldt-Rasmussen U. Pegvisomant Treatment in a 4-Year-Old Girl with Neurofibromatosis Type 1. Horm Res 2006;65:1–5
 Boyce AM, Glover M, Kelly MH, Brillante BA, Butman JA, Fitzgibbon EJ, Brewer CC, Zalewski CK, Cutler Peck CM, Kim J, Collins MT. Optic Neuropathy in McCune-Albright Syndrome: Effects of Early Diagnosis and Treatment of Growth Hormone Excess. J Clin Endocrinol Metab. Jan 2013; 98(1): E126–134.
 Laron Z, Klinger B. Effect of insulin-like growth factor-I treatment on serum androgens and testicular and penile size in males with Laron syndrome (primary growth hormone resistance). Eur J Endocrinol. 1998 Feb;138(2):176-80

**There is no actual or potential conflict of interest related to this poster** *Photos presented with patient's consent*